Neuropsychopharmacology and Toxicology Program, College of Pharmacy, Kangwon National University, Chunchon, 24341, Republic of Korea.
Department of Pharmacology, School of Pharmacy, Sungkyunkwan University, Suwon, 16419, Republic of Korea.
Mol Neurobiol. 2018 Oct;55(10):7802-7821. doi: 10.1007/s12035-018-0938-7. Epub 2018 Feb 22.
We investigated whether a specific serotonin (5-HT) receptor-mediated mechanism was involved in dextromethorphan (DM)-induced serotonergic behaviors. We firstly observed that the activation of 5-HT receptor, but not 5-HT receptor, contributed to DM-induced serotonergic behaviors in mice. We aimed to determine whether the upregulation of 5-HT receptor induced by DM facilitates the specific induction of certain PKC isoform, because previous reports suggested that 5-HT receptor activates protein kinase C (PKC). A high dose of DM (80 mg/kg, i.p.) induced a selective induction of PKCδ out of PKCα, PKCβI, PKCβII, PKCξ, and PKCδ in the hypothalamus of wild-type (WT) mice. More importantly, 5-HT receptor co-immunoprecipitated PKCδ in the presence of DM. Consistently, rottlerin, a pharmacological inhibitor of PKCδ, or PKCδ knockout significantly protected against increases in 5-HT receptor gene expression, 5-HT turnover rate, and serotonergic behaviors induced by DM. Treatment with DM resulted in an initial increase in nuclear factor erythroid-2-related factor 2 (Nrf2) nuclear translocation and DNA-binding activity, γ-glutamylcysteine (GCL) mRNA expression, and glutathione (GSH) level. This compensative induction was further potentiated by rottlerin or PKCδ knockout. However, GCL mRNA and GSH/GSSG levels were decreased 6 and 12 h post-DM. These decreases were attenuated by PKCδ inhibition. Our results suggest that interaction between 5-HT receptor and PKCδ is critical for inducing DM-induced serotonergic behaviors and that inhibition of PKCδ attenuates the serotonergic behaviors via downregulation of 5-HT receptor and upregulation of Nrf2-dependent GSH synthesis.
我们研究了特定的 5-羟色胺(5-HT)受体介导的机制是否参与了右美沙芬(DM)诱导的 5-羟色胺能行为。我们首先观察到,5-HT 受体的激活,而不是 5-HT 受体的激活,有助于小鼠中 DM 诱导的 5-羟色胺能行为。我们旨在确定 DM 诱导的 5-HT 受体上调是否有助于特定诱导某些 PKC 同工型,因为先前的报告表明 5-HT 受体激活蛋白激酶 C(PKC)。DM 的高剂量(80mg/kg,ip)在野生型(WT)小鼠的下丘脑诱导了 PKCδ而不是 PKCα、PKCβI、PKCβII、PKCξ和 PKCδ的选择性诱导。更重要的是,DM 存在时,5-HT 受体与 PKCδ共免疫沉淀。一致地,PKCδ 的药理学抑制剂罗特林或 PKCδ 敲除显著防止 DM 诱导的 5-HT 受体基因表达、5-HT 周转率和 5-羟色胺能行为的增加。DM 治疗导致核因子红细胞 2 相关因子 2(Nrf2)核易位和 DNA 结合活性、γ-谷氨酰半胱氨酸(GCL)mRNA 表达和谷胱甘肽(GSH)水平的初始增加。这种代偿性诱导进一步被罗特林或 PKCδ 敲除增强。然而,GCL mRNA 和 GSH/GSSG 水平在 DM 后 6 和 12 小时降低。这种降低被 PKCδ 抑制减弱。我们的结果表明,5-HT 受体和 PKCδ 之间的相互作用对于诱导 DM 诱导的 5-羟色胺能行为至关重要,并且 PKCδ 抑制通过下调 5-HT 受体和上调 Nrf2 依赖性 GSH 合成来减弱 5-羟色胺能行为。